Hualan Biological Vaccine Inc.

301207

CNE1000058J9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
17.23 ^CNY	-0.52%		-0.92%	-38.02%

Jul. 02	Tranche Update on Hualan Biological Vaccine Inc.'s Equity Buyback Plan announced on June 7, 2024.	CI
Jun. 07	Hualan Biological Vaccine Inc. Announces Dividend Implementation for 2023, Payable on 14 June 2024	CI

Tranche Update on Hualan Biological Vaccine Inc.'s Equity Buyback Plan announced on June 7, 2024.

July 02, 2024 at 03:41 pm EDT

From June 5, 2024 to June 30, 2024, the company has repurchased 2,210,000 shares, representing 0.37% for CNY 39.96 million. With this, the company has completed the repurchase of 2,210,000 shares, representing 0.37% for CNY 39.96 million under the buyback announced on June 7, 2024.

Latest news about Hualan Biological Vaccine Inc.

Tranche Update on Hualan Biological Vaccine Inc.'s Equity Buyback Plan announced on June 7, 2024.	Jul. 02	CI
Hualan Biological Vaccine Inc. Announces Dividend Implementation for 2023, Payable on 14 June 2024	Jun. 07	CI
Hualan Biological Vaccine to Buy Back Up to 200 Million Yuan Worth of Shares	Jun. 07	MT
Hualan Biological Vaccine Inc. announces an Equity Buyback for CNY 200 million worth of its shares.	Jun. 06	CI
Hualan Biological Vaccine Chairman Proposes Up to 200 Million Yuan Buyback	Jun. 05	MT
Hualan Biological Vaccine Inc. authorizes a Buyback Plan.	Jun. 04	CI
Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023	Apr. 01	CI
Hualan Biological Vaccine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Certain A Shares of Hualan Biological Bacterin Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024.	Feb. 17	CI
Hualan Biological Bacterin Inc. has Changed its Name to Hualan Biological Vaccine Inc	Nov. 16	CI
Hualan Biological Vaccine Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hualan Biological Bacterin Inc.(XSEC:301207) added to S&P Global BMI Index	23-09-18	CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Hualan Biological Bacterin Inc. Announces Implementation of Final Profit Distribution Plan of A Shares for 2022, Payable on 07 June 2023	23-05-31	CI
Hualan Biological Bacterin Inc. Approves Cash Dividend for the Year 2022	23-04-24	CI
Hualan Biological Bacterin Inc. Announces Board Elections	23-04-24	CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Hualan Biological Bacterin to Return to Profit in Q1	23-04-10	MT
Hualan Biological Bacterin Inc. Proposes Final Cash Dividend for 2022	23-03-30	CI
Hualan Biological Bacterin Gets Certification for Tetanus Vaccine	23-02-28	MT
Certain A Shares of Hualan Biological Bacterin Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2023.	23-02-17	CI
Hualan Biological Bacterin Registers Freeze-Dried Human Rabies Vaccine	23-02-01	MT
Hualan Biological Bacterin Inc.(SZSE:301207) added to Shenzhen Stock Exchange Component Index	22-12-12	CI
Hualan Biological Bacterin Inc.(SZSE:301207) added to Shenzhen Stock Exchange Component A Share Index	22-12-12	CI

Chart Hualan Biological Vaccine Inc.

Duration

Period

More charts

Company Profile

Hualan Biological Vaccine Inc, formerly Hualan Biological Bacterin Inc, is a China-based company principally engaged in the research, development, production and sales of human vaccines. The Company's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The Company's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The Company's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hualan Biological Vaccine Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.23 CNY

Average target price

29.3 CNY

Spread / Average Target

+70.05%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
HUALAN BIOLOGICAL VACCINE INC.	-38.02%	1.43B
CSL LIMITED	+6.96%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.29%	42.63B
BIOGEN INC.	-11.09%	33.5B
UCB	+82.32%	29.77B
BIOMARIN PHARMACEUTICAL INC.	-11.82%	16.14B
INCYTE CORPORATION	+1.39%	14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.13%	11.55B
ALTEOGEN INC.	+176.65%	10.53B
SWEDISH ORPHAN BIOVITRUM AB	+6.74%	9.2B

Biopharmaceuticals

Hualan Biological Vaccine Inc.

Equities

301207

CNE1000058J9

Pharmaceuticals

Tranche Update on Hualan Biological Vaccine Inc.'s Equity Buyback Plan announced on June 7, 2024.

Latest news about Hualan Biological Vaccine Inc.

Chart Hualan Biological Vaccine Inc.

Company Profile

Income Statement Evolution

Ratings for Hualan Biological Vaccine Inc.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals